The Europe Veterinary Pain Management Market should witness market growth of 6.0% CAGR during the forecast period (2023-2030).
Non-pharmaceutical pain management strategies are becoming increasingly common, which is a significant trend in the industry and has tremendous potential for future market growth. As they provide benefits over conventional pharmaceutical alternatives for pain management, methods, including laser and electromagnetic therapy, are used more often. While electromagnetic therapy uses a magnetic field, radio waves, or any other forms of electromagnetic radiation at a specific intensity, laser therapy treats inflammation and pain by using light energy on the affected area. These treatments target the cause of pain, eliminating the need for invasive, painful surgeries and further painkiller use. Additionally, these treatments aid patients in accelerating their healing process.
Due to increased surgical procedures brought on by more illnesses and the demand for enhanced pet care, pharmaceuticals for pain management are being utilized increasingly. Non-steroidal anti-inflammatory medicines, local anaesthetics, opioids, and N-methyl-D-aspartate (NMDA) antagonist treatments such as laser therapy and electromagnetic therapy are some of the pain-relieving medications available in the market. The pain's cause, level, and length determine the most effective treatment method.
Most people in Europe own pets, considered their closest friends and cherished family members. The percentage of houses with at least one pet animal has increased, and people are spending an increasing income on their pets, improving the industry's revenue. The pet care industry is still experiencing growth due to the rise in adoption rates and the humanization of animals. The European Pet Food Federation (FEDIAF) has released its most recent yearly statistics as of June 2018, demonstrating that pet ownership in Europe remains quite prevalent, with an estimated 80 million European residences keeping at least one pet. The region's expanding pet ownership rates and rising pet healthcare spending are anticipated to promote the expansion of the market.
The Germany market dominated the Europe Veterinary Pain Management Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $168.6 million by 2030. The UK market is estimated to grow at a CAGR of 5.1% during (2023-2030). Additionally, The France market would register a CAGR of 6.8% during (2023-2030).
Based on Animal type, the market is segmented into Livestock Animal and Companion Animal. Based on End-Use, the market is segmented into Hospitals & Clinics and Others. Based on Indication, the market is segmented into Osteoarthritis, Post-operative pain, and Others. Based on Product, the market is segmented into NSAIDs, Opioids, Anesthetics and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Boehringer Ingelheim International GmbH, Bayer AG, Zoetis, Inc., Merck & Co., Inc., Elanco Animal Health, Inc., Zomedica Corp. (Assisi Animal Health), Norbrook Laboratories Limited, Ceva Santé Animale, Dechra Pharmaceuticals PLC, and Vetoquinol SA (Soparfin SCA)
Non-pharmaceutical pain management strategies are becoming increasingly common, which is a significant trend in the industry and has tremendous potential for future market growth. As they provide benefits over conventional pharmaceutical alternatives for pain management, methods, including laser and electromagnetic therapy, are used more often. While electromagnetic therapy uses a magnetic field, radio waves, or any other forms of electromagnetic radiation at a specific intensity, laser therapy treats inflammation and pain by using light energy on the affected area. These treatments target the cause of pain, eliminating the need for invasive, painful surgeries and further painkiller use. Additionally, these treatments aid patients in accelerating their healing process.
Due to increased surgical procedures brought on by more illnesses and the demand for enhanced pet care, pharmaceuticals for pain management are being utilized increasingly. Non-steroidal anti-inflammatory medicines, local anaesthetics, opioids, and N-methyl-D-aspartate (NMDA) antagonist treatments such as laser therapy and electromagnetic therapy are some of the pain-relieving medications available in the market. The pain's cause, level, and length determine the most effective treatment method.
Most people in Europe own pets, considered their closest friends and cherished family members. The percentage of houses with at least one pet animal has increased, and people are spending an increasing income on their pets, improving the industry's revenue. The pet care industry is still experiencing growth due to the rise in adoption rates and the humanization of animals. The European Pet Food Federation (FEDIAF) has released its most recent yearly statistics as of June 2018, demonstrating that pet ownership in Europe remains quite prevalent, with an estimated 80 million European residences keeping at least one pet. The region's expanding pet ownership rates and rising pet healthcare spending are anticipated to promote the expansion of the market.
The Germany market dominated the Europe Veterinary Pain Management Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $168.6 million by 2030. The UK market is estimated to grow at a CAGR of 5.1% during (2023-2030). Additionally, The France market would register a CAGR of 6.8% during (2023-2030).
Based on Animal type, the market is segmented into Livestock Animal and Companion Animal. Based on End-Use, the market is segmented into Hospitals & Clinics and Others. Based on Indication, the market is segmented into Osteoarthritis, Post-operative pain, and Others. Based on Product, the market is segmented into NSAIDs, Opioids, Anesthetics and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Boehringer Ingelheim International GmbH, Bayer AG, Zoetis, Inc., Merck & Co., Inc., Elanco Animal Health, Inc., Zomedica Corp. (Assisi Animal Health), Norbrook Laboratories Limited, Ceva Santé Animale, Dechra Pharmaceuticals PLC, and Vetoquinol SA (Soparfin SCA)
Scope of the Study
By Animal type
- Livestock Animal
- Companion Animal
By End-Use
- Hospitals & Clinics
- Others
By Indication
- Osteoarthritis
- Post-operative pain
- Others
By Product
- NSAIDs
- Opioids
- Anesthetics
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Boehringer Ingelheim International GmbH
- Bayer AG
- Zoetis, Inc.
- Merck & Co., Inc.
- Elanco Animal Health, Inc.
- Zomedica Corp. (Assisi Animal Health)
- Norbrook Laboratories Limited
- Ceva Santé Animale
- Dechra Pharmaceuticals PLC
- Vetoquinol SA (Soparfin SCA)
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 5. Europe Veterinary Pain Management Market by Animal type
Chapter 6. Europe Veterinary Pain Management Market by End-use
Chapter 7. Europe Veterinary Pain Management Market by Indication
Chapter 8. Europe Veterinary Pain Management Market by Product
Chapter 9. Europe Veterinary Pain Management Market by Country
Chapter 10. Company Profiles
Companies Mentioned
- Boehringer Ingelheim International GmbH
- Bayer AG
- Zoetis, Inc.
- Merck & Co., Inc.
- Elanco Animal Health, Inc.
- Zomedica Corp. (Assisi Animal Health)
- Norbrook Laboratories Limited
- Ceva Santé Animale
- Dechra Pharmaceuticals PLC
- Vetoquinol SA (Soparfin SCA)
Methodology
LOADING...
